EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Liraglutide: a new option in the management of type 2 diabetes

Milan K Piya, Abd A Tahrani, Anthony H Barnett

Future Prescriber · 2008

DOI: 10.1002/fps.10 ↗
AstrattDettalji biblijografiċi

Astratt

Abstract Type 2 diabetes mellitus (T2DM) is a global epidemic with an expected prevalence of 380 million in 2025 worldwide 1 and over 2.5 million by 2010 in the UK. 2 Diabetes is a progres‐sive disease which leads to macro and microvascular complications and reduced life expectancy. 2 Furthermore, diabetes‐related complications have been shown to worsen patients' quality of life. 3,4 Copyright © 2008 John Wiley & Sons, Ltd.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →